JP2012524794A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012524794A5 JP2012524794A5 JP2012507341A JP2012507341A JP2012524794A5 JP 2012524794 A5 JP2012524794 A5 JP 2012524794A5 JP 2012507341 A JP2012507341 A JP 2012507341A JP 2012507341 A JP2012507341 A JP 2012507341A JP 2012524794 A5 JP2012524794 A5 JP 2012524794A5
- Authority
- JP
- Japan
- Prior art keywords
- quinazolin
- dimethoxy
- ethoxy
- dimethylphenyl
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229910052739 hydrogen Inorganic materials 0.000 claims 22
- 239000001257 hydrogen Substances 0.000 claims 20
- 150000002431 hydrogen Chemical class 0.000 claims 18
- -1 2-hydroxy-2-methylpropoxy, 2-hydroxyethoxy, methoxy, benzyloxyethoxy, 2,3-dihydroxypropoxy, aminocarbonylethoxy, methylaminocarbonylethoxy Chemical group 0.000 claims 14
- 125000000623 heterocyclic group Chemical group 0.000 claims 12
- 229910052736 halogen Inorganic materials 0.000 claims 10
- 150000002367 halogens Chemical class 0.000 claims 10
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 8
- 125000000217 alkyl group Chemical group 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 5
- 229910052760 oxygen Inorganic materials 0.000 claims 5
- 102000004889 Interleukin-6 Human genes 0.000 claims 4
- 108090001005 Interleukin-6 Proteins 0.000 claims 4
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 claims 4
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 4
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- MDOGCKRWWGCWCZ-UHFFFAOYSA-N 2-(4-hydroxy-3,5-dimethylphenyl)-5-methoxy-7-(2-methoxyethoxy)-3H-quinazolin-4-one Chemical compound C=1C(OCCOC)=CC(OC)=C(C(N2)=O)C=1N=C2C1=CC(C)=C(O)C(C)=C1 MDOGCKRWWGCWCZ-UHFFFAOYSA-N 0.000 claims 2
- HSIQEDUCBAIUCD-UHFFFAOYSA-N 2-(4-hydroxy-3,5-dimethylphenyl)-5-methoxy-7-(2-phenylmethoxyethoxy)-3H-quinazolin-4-one Chemical compound C=1C=2N=C(C=3C=C(C)C(O)=C(C)C=3)NC(=O)C=2C(OC)=CC=1OCCOCC1=CC=CC=C1 HSIQEDUCBAIUCD-UHFFFAOYSA-N 0.000 claims 2
- ZBVMRQYXKHKMCA-UHFFFAOYSA-N 2-(4-hydroxy-3,5-dimethylphenyl)-5-methoxy-7-[2-(pyridin-3-ylmethoxy)ethoxy]-3H-quinazolin-4-one Chemical compound C=1C=2N=C(C=3C=C(C)C(O)=C(C)C=3)NC(=O)C=2C(OC)=CC=1OCCOCC1=CC=CN=C1 ZBVMRQYXKHKMCA-UHFFFAOYSA-N 0.000 claims 2
- GGYCKROERKJIPH-UHFFFAOYSA-N 2-(4-hydroxy-3,5-dimethylphenyl)-6-(pyridin-2-ylamino)-3H-quinazolin-4-one Chemical compound CC1=C(O)C(C)=CC(C=2NC(=O)C3=CC(NC=4N=CC=CC=4)=CC=C3N=2)=C1 GGYCKROERKJIPH-UHFFFAOYSA-N 0.000 claims 2
- SRTWCIMCOKZRSD-UHFFFAOYSA-N 2-(4-hydroxy-3,5-dimethylphenyl)-6-(pyridin-4-ylamino)-3H-quinazolin-4-one Chemical compound CC1=C(O)C(C)=CC(C=2NC(=O)C3=CC(NC=4C=CN=CC=4)=CC=C3N=2)=C1 SRTWCIMCOKZRSD-UHFFFAOYSA-N 0.000 claims 2
- RHYDBUQWKLDSSH-UHFFFAOYSA-N 2-(4-hydroxy-3,5-dimethylphenyl)-6-[(4-methylpiperazin-1-yl)methyl]-3H-quinazolin-4-one Chemical compound C1CN(C)CCN1CC1=CC=C(N=C(NC2=O)C=3C=C(C)C(O)=C(C)C=3)C2=C1 RHYDBUQWKLDSSH-UHFFFAOYSA-N 0.000 claims 2
- APZNQSZDPRARPQ-UHFFFAOYSA-N 2-(4-hydroxy-3,5-dimethylphenyl)-7-methoxy-5-(2-methoxyethoxy)-3H-quinazolin-4-one Chemical compound N1C(=O)C=2C(OCCOC)=CC(OC)=CC=2N=C1C1=CC(C)=C(O)C(C)=C1 APZNQSZDPRARPQ-UHFFFAOYSA-N 0.000 claims 2
- LKVSVQSRTKWFIL-UHFFFAOYSA-N 2-[2-(2-hydroxyethyl)-1h-indol-6-yl]-5,7-dimethoxy-1h-quinazolin-4-one Chemical compound C1=C2C=C(CCO)NC2=CC(C2=NC=3C(C(N2)=O)=C(OC)C=C(C=3)OC)=C1 LKVSVQSRTKWFIL-UHFFFAOYSA-N 0.000 claims 2
- PNFCSROGAPWESA-UHFFFAOYSA-N 2-[2-(hydroxymethyl)-1-benzofuran-5-yl]-5,7-dimethoxy-1h-quinazolin-4-one Chemical compound C1=C2OC(CO)=CC2=CC(C2=NC=3C(C(N2)=O)=C(OC)C=C(C=3)OC)=C1 PNFCSROGAPWESA-UHFFFAOYSA-N 0.000 claims 2
- BYWNULLIYPUOEP-UHFFFAOYSA-N 2-[2-(hydroxymethyl)-1-benzofuran-5-yl]-5-methoxy-7-(2-phenylmethoxyethoxy)-1h-quinazolin-4-one Chemical compound C=1C=2N=C(C=3C=C4C=C(CO)OC4=CC=3)NC(=O)C=2C(OC)=CC=1OCCOCC1=CC=CC=C1 BYWNULLIYPUOEP-UHFFFAOYSA-N 0.000 claims 2
- WALLOGAYHQWBIU-UHFFFAOYSA-N 2-[3,5-dimethyl-4-(2-phenylmethoxyethoxy)phenyl]-5,7-dimethoxy-1h-pyrido[2,3-d]pyrimidin-4-one Chemical compound N=1C(OC)=CC(OC)=C(C(N2)=O)C=1N=C2C(C=C1C)=CC(C)=C1OCCOCC1=CC=CC=C1 WALLOGAYHQWBIU-UHFFFAOYSA-N 0.000 claims 2
- GUXJETKNLPSMFR-UHFFFAOYSA-N 2-[3,5-dimethyl-4-[2-(1,2-oxazol-3-ylamino)ethoxy]phenyl]-5,7-dimethoxy-1h-quinazolin-4-one Chemical compound C=1C(OC)=CC(OC)=C(C(N2)=O)C=1N=C2C(C=C1C)=CC(C)=C1OCCNC=1C=CON=1 GUXJETKNLPSMFR-UHFFFAOYSA-N 0.000 claims 2
- PYLDFPVGGNHJSO-UHFFFAOYSA-N 2-[3,5-dimethyl-4-[2-(2,2,2-trifluoroethylamino)ethoxy]phenyl]-5,7-dimethoxy-1h-quinazolin-4-one Chemical compound C=1C(OC)=CC(OC)=C(C(N2)=O)C=1N=C2C1=CC(C)=C(OCCNCC(F)(F)F)C(C)=C1 PYLDFPVGGNHJSO-UHFFFAOYSA-N 0.000 claims 2
- JHHFAFANAXHNSU-UHFFFAOYSA-N 2-[3,5-dimethyl-4-[2-(methylamino)ethoxy]phenyl]-5,7-dimethoxy-1h-quinazolin-4-one Chemical compound C1=C(C)C(OCCNC)=C(C)C=C1C1=NC2=CC(OC)=CC(OC)=C2C(=O)N1 JHHFAFANAXHNSU-UHFFFAOYSA-N 0.000 claims 2
- ZXCSEHMIVFVIHL-UHFFFAOYSA-N 2-[3,5-dimethyl-4-[2-(propan-2-ylamino)ethoxy]phenyl]-5,7-dimethoxy-1h-quinazolin-4-one Chemical compound C=1C(OC)=CC(OC)=C(C(N2)=O)C=1N=C2C1=CC(C)=C(OCCNC(C)C)C(C)=C1 ZXCSEHMIVFVIHL-UHFFFAOYSA-N 0.000 claims 2
- SULXIQQOIHSELL-UHFFFAOYSA-N 2-[3,5-dimethyl-4-[2-(pyrimidin-2-ylamino)ethoxy]phenyl]-5,7-dimethoxy-1h-quinazolin-4-one Chemical compound C=1C(OC)=CC(OC)=C(C(N2)=O)C=1N=C2C(C=C1C)=CC(C)=C1OCCNC1=NC=CC=N1 SULXIQQOIHSELL-UHFFFAOYSA-N 0.000 claims 2
- IPZVRQMTFBFZMB-UHFFFAOYSA-N 2-[3,5-dimethyl-4-[2-[(3-methyl-1,2,4-oxadiazol-5-yl)amino]ethoxy]phenyl]-5,7-dimethoxy-1h-quinazolin-4-one Chemical compound C=1C(OC)=CC(OC)=C(C(N2)=O)C=1N=C2C(C=C1C)=CC(C)=C1OCCNC1=NC(C)=NO1 IPZVRQMTFBFZMB-UHFFFAOYSA-N 0.000 claims 2
- NWUMWUJCWZEQPR-UHFFFAOYSA-N 2-[3,5-dimethyl-4-[2-[(5-methyl-1,2-oxazol-3-yl)amino]ethoxy]phenyl]-5,7-dimethoxy-1h-quinazolin-4-one Chemical compound C=1C(OC)=CC(OC)=C(C(N2)=O)C=1N=C2C(C=C1C)=CC(C)=C1OCCNC=1C=C(C)ON=1 NWUMWUJCWZEQPR-UHFFFAOYSA-N 0.000 claims 2
- FYRBPTYMWCKKMI-UHFFFAOYSA-N 2-[4-(2,3-dihydroxypropoxy)-3,5-dimethylphenyl]-5,7-dimethoxy-1h-quinazolin-4-one Chemical compound C=1C(OC)=CC(OC)=C(C(N2)=O)C=1N=C2C1=CC(C)=C(OCC(O)CO)C(C)=C1 FYRBPTYMWCKKMI-UHFFFAOYSA-N 0.000 claims 2
- IEFZYZBRJHLPQL-UHFFFAOYSA-N 2-[4-(2-hydroxyethoxy)-3,5-dimethylphenyl]-5,7-di(propan-2-yloxy)-1h-quinazolin-4-one Chemical compound C=1C(OC(C)C)=CC(OC(C)C)=C(C(N2)=O)C=1N=C2C1=CC(C)=C(OCCO)C(C)=C1 IEFZYZBRJHLPQL-UHFFFAOYSA-N 0.000 claims 2
- KAJOGFKWTONJNI-UHFFFAOYSA-N 2-[4-(2-hydroxyethoxy)-3,5-dimethylphenyl]-5,7-dimethoxy-6-(morpholin-4-ylmethyl)-1h-quinazolin-4-one Chemical compound COC1=CC=2N=C(C=3C=C(C)C(OCCO)=C(C)C=3)NC(=O)C=2C(OC)=C1CN1CCOCC1 KAJOGFKWTONJNI-UHFFFAOYSA-N 0.000 claims 2
- LGPBXJVSEXVOLI-UHFFFAOYSA-N 2-[4-(2-hydroxyethoxy)-3,5-dimethylphenyl]-5,7-dimethyl-1h-pyrido[2,3-d]pyrimidin-4-one Chemical compound N=1C(C)=CC(C)=C(C(N2)=O)C=1N=C2C1=CC(C)=C(OCCO)C(C)=C1 LGPBXJVSEXVOLI-UHFFFAOYSA-N 0.000 claims 2
- ZSNMJTCQIWYPEJ-UHFFFAOYSA-N 2-[4-(2-hydroxyethoxy)-3,5-dimethylphenyl]-5-methoxy-7-(2-phenylmethoxyethoxy)-1h-quinazolin-4-one Chemical compound C=1C=2N=C(C=3C=C(C)C(OCCO)=C(C)C=3)NC(=O)C=2C(OC)=CC=1OCCOCC1=CC=CC=C1 ZSNMJTCQIWYPEJ-UHFFFAOYSA-N 0.000 claims 2
- XXHXTYXZQCOHLN-UHFFFAOYSA-N 2-[4-(2-hydroxyethoxy)-3,5-dimethylphenyl]-6-(morpholin-4-ylmethyl)-1h-quinazolin-4-one Chemical compound CC1=C(OCCO)C(C)=CC(C=2NC(=O)C3=CC(CN4CCOCC4)=CC=C3N=2)=C1 XXHXTYXZQCOHLN-UHFFFAOYSA-N 0.000 claims 2
- DSFBHHRWCDCSHI-UHFFFAOYSA-N 2-[4-(2-hydroxyethoxy)-3,5-dimethylphenyl]-6-[(4-methylpiperazin-1-yl)methyl]-1h-quinazolin-4-one Chemical compound C1CN(C)CCN1CC1=CC=C(N=C(NC2=O)C=3C=C(C)C(OCCO)=C(C)C=3)C2=C1 DSFBHHRWCDCSHI-UHFFFAOYSA-N 0.000 claims 2
- YURGJGIKUMNQAG-UHFFFAOYSA-N 2-[4-(2-hydroxyethoxy)-3,5-dimethylphenyl]-6-morpholin-4-yl-1h-quinazolin-4-one Chemical compound CC1=C(OCCO)C(C)=CC(C=2NC(=O)C3=CC(=CC=C3N=2)N2CCOCC2)=C1 YURGJGIKUMNQAG-UHFFFAOYSA-N 0.000 claims 2
- IQHGJLJMQNOOOM-UHFFFAOYSA-N 2-[4-(2-hydroxyethoxy)-3,5-dimethylphenyl]-7-methoxy-1h-quinazolin-4-one Chemical compound C=1C(OC)=CC=C(C(N2)=O)C=1N=C2C1=CC(C)=C(OCCO)C(C)=C1 IQHGJLJMQNOOOM-UHFFFAOYSA-N 0.000 claims 2
- BUTMYQZRONUNRA-UHFFFAOYSA-N 2-[4-(2-hydroxyethoxy)-3,5-dimethylphenyl]-8-methoxy-1h-quinazolin-4-one Chemical compound COC1=CC=CC(C(N2)=O)=C1N=C2C1=CC(C)=C(OCCO)C(C)=C1 BUTMYQZRONUNRA-UHFFFAOYSA-N 0.000 claims 2
- FPEWRFDXDFCNDC-UHFFFAOYSA-N 2-[4-(2-hydroxyethoxy)naphthalen-1-yl]-5,7-dimethoxy-1h-quinazolin-4-one Chemical compound C1=CC=C2C(C3=NC=4C(C(N3)=O)=C(OC)C=C(C=4)OC)=CC=C(OCCO)C2=C1 FPEWRFDXDFCNDC-UHFFFAOYSA-N 0.000 claims 2
- WBTCFZCMHRLXQO-UHFFFAOYSA-N 2-[4-(2-hydroxyethoxy)phenyl]-5,7-dimethoxy-1h-quinazolin-4-one Chemical compound C=1C(OC)=CC(OC)=C(C(N2)=O)C=1N=C2C1=CC=C(OCCO)C=C1 WBTCFZCMHRLXQO-UHFFFAOYSA-N 0.000 claims 2
- HUOQPMXIZKHHSW-UHFFFAOYSA-N 2-[4-(3-hydroxypropyl)-3,5-dimethoxyphenyl]-5,7-dimethoxy-1h-quinazolin-4-one Chemical compound C=1C(OC)=CC(OC)=C(C(N2)=O)C=1N=C2C1=CC(OC)=C(CCCO)C(OC)=C1 HUOQPMXIZKHHSW-UHFFFAOYSA-N 0.000 claims 2
- NHSUSPHYOQXLKI-UHFFFAOYSA-N 2-[4-(3-hydroxypropyl)-3-methoxyphenyl]-5,7-dimethoxy-1h-quinazolin-4-one Chemical compound C=1C(OC)=CC(OC)=C(C(N2)=O)C=1N=C2C1=CC=C(CCCO)C(OC)=C1 NHSUSPHYOQXLKI-UHFFFAOYSA-N 0.000 claims 2
- PNJZRVOXBUCTOW-UHFFFAOYSA-N 2-[4-(5,7-dimethoxy-4-oxo-1h-quinazolin-2-yl)-2,6-dimethylphenoxy]-n-(4-methoxyphenyl)acetamide Chemical compound C1=CC(OC)=CC=C1NC(=O)COC1=C(C)C=C(C=2NC(=O)C3=C(OC)C=C(OC)C=C3N=2)C=C1C PNJZRVOXBUCTOW-UHFFFAOYSA-N 0.000 claims 2
- CNLOLXKDVFTTLW-UHFFFAOYSA-N 2-[4-(5,7-dimethoxy-4-oxo-1h-quinazolin-2-yl)-2,6-dimethylphenoxy]-n-methylacetamide Chemical compound C1=C(C)C(OCC(=O)NC)=C(C)C=C1C1=NC2=CC(OC)=CC(OC)=C2C(=O)N1 CNLOLXKDVFTTLW-UHFFFAOYSA-N 0.000 claims 2
- YTLOXNQXTWFAJB-UHFFFAOYSA-N 2-[4-(5,7-dimethoxy-4-oxo-1h-quinazolin-2-yl)-2,6-dimethylphenoxy]ethylcyanamide Chemical compound C=1C(OC)=CC(OC)=C(C(N2)=O)C=1N=C2C1=CC(C)=C(OCCNC#N)C(C)=C1 YTLOXNQXTWFAJB-UHFFFAOYSA-N 0.000 claims 2
- ZLYCVBKVYCOXGT-UHFFFAOYSA-N 2-[4-[2-(dimethylamino)ethoxy]-3,5-dimethylphenyl]-5,7-dimethoxy-1h-quinazolin-4-one Chemical compound C=1C(OC)=CC(OC)=C(C(N2)=O)C=1N=C2C1=CC(C)=C(OCCN(C)C)C(C)=C1 ZLYCVBKVYCOXGT-UHFFFAOYSA-N 0.000 claims 2
- IHTUFOIGRIKCEF-UHFFFAOYSA-N 2-[4-[2-[(4,6-dimethoxypyrimidin-2-yl)amino]ethoxy]-3,5-dimethylphenyl]-5,7-dimethoxy-1h-quinazolin-4-one Chemical compound C=1C(OC)=CC(OC)=C(C(N2)=O)C=1N=C2C(C=C1C)=CC(C)=C1OCCNC1=NC(OC)=CC(OC)=N1 IHTUFOIGRIKCEF-UHFFFAOYSA-N 0.000 claims 2
- JJBNVQFJGXYJLO-UHFFFAOYSA-N 5,7-difluoro-2-[4-(2-hydroxyethoxy)-3,5-dimethylphenyl]-1h-quinazolin-4-one Chemical compound CC1=C(OCCO)C(C)=CC(C=2NC(=O)C3=C(F)C=C(F)C=C3N=2)=C1 JJBNVQFJGXYJLO-UHFFFAOYSA-N 0.000 claims 2
- GTUAWCNRLUGFCM-UHFFFAOYSA-N 5,7-dimethoxy-2-[3-methyl-4-[2-[(5-phenyl-1h-1,2,4-triazol-3-yl)amino]ethoxy]phenyl]-1h-quinazolin-4-one Chemical compound C=1C(OC)=CC(OC)=C(C(N2)=O)C=1N=C2C(C=C1C)=CC=C1OCCNC(N1)=NN=C1C1=CC=CC=C1 GTUAWCNRLUGFCM-UHFFFAOYSA-N 0.000 claims 2
- YZJRQXLNLOJQBC-UHFFFAOYSA-N 5-[2-(dimethylamino)ethoxy]-2-(4-hydroxy-3,5-dimethylphenyl)-7-methoxy-3H-quinazolin-4-one Chemical compound C=1C(OC)=CC(OCCN(C)C)=C(C(N2)=O)C=1N=C2C1=CC(C)=C(O)C(C)=C1 YZJRQXLNLOJQBC-UHFFFAOYSA-N 0.000 claims 2
- HGUHCPZTHPCUIQ-UHFFFAOYSA-N 5-chloro-2-[4-(2-hydroxyethoxy)-3,5-dimethylphenyl]-1h-quinazolin-4-one Chemical compound CC1=C(OCCO)C(C)=CC(C=2NC(=O)C3=C(Cl)C=CC=C3N=2)=C1 HGUHCPZTHPCUIQ-UHFFFAOYSA-N 0.000 claims 2
- JMCGLFZNIJLKPI-UHFFFAOYSA-N 7-(2-aminoethoxy)-2-(4-hydroxy-3,5-dimethylphenyl)-5-methoxy-3H-quinazolin-4-one Chemical compound N1C(=O)C=2C(OC)=CC(OCCN)=CC=2N=C1C1=CC(C)=C(O)C(C)=C1 JMCGLFZNIJLKPI-UHFFFAOYSA-N 0.000 claims 2
- PWDSZMUIVXNRGI-UHFFFAOYSA-N 7-[2-(dimethylamino)ethoxy]-2-(4-hydroxy-3,5-dimethylphenyl)-3H-quinazolin-4-one Chemical compound C=1C(OCCN(C)C)=CC=C(C(N2)=O)C=1N=C2C1=CC(C)=C(O)C(C)=C1 PWDSZMUIVXNRGI-UHFFFAOYSA-N 0.000 claims 2
- ISDAEGUKMVOWHV-UHFFFAOYSA-N 7-chloro-2-[4-(2-hydroxyethoxy)-3,5-dimethylphenyl]-1h-quinazolin-4-one Chemical compound CC1=C(OCCO)C(C)=CC(C=2NC(=O)C3=CC=C(Cl)C=C3N=2)=C1 ISDAEGUKMVOWHV-UHFFFAOYSA-N 0.000 claims 2
- XYXAPLAQQRDOOI-UHFFFAOYSA-N 8-chloro-2-[4-(2-hydroxyethoxy)-3,5-dimethylphenyl]-1h-quinazolin-4-one Chemical compound CC1=C(OCCO)C(C)=CC(C=2NC(=O)C3=CC=CC(Cl)=C3N=2)=C1 XYXAPLAQQRDOOI-UHFFFAOYSA-N 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 claims 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- GITDYDRJUITKMH-UHFFFAOYSA-N N-[[2-(4-hydroxy-3,5-dimethylphenyl)-4-oxo-3H-quinazolin-6-yl]methyl]methanesulfonamide Chemical compound CC1=C(O)C(C)=CC(C=2NC(=O)C3=CC(CNS(C)(=O)=O)=CC=C3N=2)=C1 GITDYDRJUITKMH-UHFFFAOYSA-N 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229910052731 fluorine Inorganic materials 0.000 claims 2
- 239000011737 fluorine Substances 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- XAQKZGVWOHQWGE-UHFFFAOYSA-N n-[2-[4-(5,7-dimethoxy-4-oxo-1h-quinazolin-2-yl)-2,6-dimethylphenoxy]ethyl]-n-methylacetamide Chemical compound C=1C(OC)=CC(OC)=C(C(N2)=O)C=1N=C2C1=CC(C)=C(OCCN(C)C(C)=O)C(C)=C1 XAQKZGVWOHQWGE-UHFFFAOYSA-N 0.000 claims 2
- PTBASXYYZNQXGP-UHFFFAOYSA-N n-[2-[4-(5,7-dimethoxy-4-oxo-1h-quinazolin-2-yl)-2,6-dimethylphenoxy]ethyl]-n-methylformamide Chemical compound C=1C(OC)=CC(OC)=C(C(N2)=O)C=1N=C2C1=CC(C)=C(OCCN(C)C=O)C(C)=C1 PTBASXYYZNQXGP-UHFFFAOYSA-N 0.000 claims 2
- MRPBLCPVJYSEHZ-UHFFFAOYSA-N n-[2-[4-(5,7-dimethoxy-4-oxo-1h-quinazolin-2-yl)-2,6-dimethylphenoxy]ethyl]formamide Chemical compound C=1C(OC)=CC(OC)=C(C(N2)=O)C=1N=C2C1=CC(C)=C(OCCNC=O)C(C)=C1 MRPBLCPVJYSEHZ-UHFFFAOYSA-N 0.000 claims 2
- JXYULCWHTVYMQB-UHFFFAOYSA-N n-[2-[4-(5,7-dimethoxy-4-oxo-1h-quinazolin-2-yl)-2,6-dimethylphenoxy]ethyl]propane-2-sulfonamide Chemical compound C=1C(OC)=CC(OC)=C(C(N2)=O)C=1N=C2C1=CC(C)=C(OCCNS(=O)(=O)C(C)C)C(C)=C1 JXYULCWHTVYMQB-UHFFFAOYSA-N 0.000 claims 2
- KJJJKBFEBDERSM-UHFFFAOYSA-N n-[2-[4-(5,7-dimethoxy-4-oxo-1h-quinazolin-2-yl)-2-methylphenoxy]ethyl]acetamide Chemical compound C=1C(OC)=CC(OC)=C(C(N2)=O)C=1N=C2C1=CC=C(OCCNC(C)=O)C(C)=C1 KJJJKBFEBDERSM-UHFFFAOYSA-N 0.000 claims 2
- JTJFFTKRYUMYHA-UHFFFAOYSA-N n-[2-[4-(6,8-dimethoxy-1-oxo-2h-isoquinolin-3-yl)-2,6-dimethylphenoxy]ethyl]formamide Chemical compound C=1C(OC)=CC(OC)=C(C(N2)=O)C=1C=C2C1=CC(C)=C(OCCNC=O)C(C)=C1 JTJFFTKRYUMYHA-UHFFFAOYSA-N 0.000 claims 2
- PLSBTFRYIVHGQQ-UHFFFAOYSA-N n-[[4-(5,7-dimethoxy-4-oxo-1h-pyrido[2,3-d]pyrimidin-2-yl)-2,6-dimethylphenyl]methyl]acetamide Chemical compound N=1C(OC)=CC(OC)=C(C(N2)=O)C=1N=C2C1=CC(C)=C(CNC(C)=O)C(C)=C1 PLSBTFRYIVHGQQ-UHFFFAOYSA-N 0.000 claims 2
- AYYRYDJWOZCCDK-UHFFFAOYSA-N n-[[4-(5,7-dimethoxy-4-oxo-1h-quinazolin-2-yl)-2,6-dimethylphenyl]methyl]acetamide Chemical compound C=1C(OC)=CC(OC)=C(C(N2)=O)C=1N=C2C1=CC(C)=C(CNC(C)=O)C(C)=C1 AYYRYDJWOZCCDK-UHFFFAOYSA-N 0.000 claims 2
- SCJYDQMKIATBOJ-UHFFFAOYSA-N n-benzyl-2-[4-(5,7-dimethoxy-4-oxo-1h-quinazolin-2-yl)-2,6-dimethylphenoxy]acetamide Chemical compound C=1C(OC)=CC(OC)=C(C(N2)=O)C=1N=C2C(C=C1C)=CC(C)=C1OCC(=O)NCC1=CC=CC=C1 SCJYDQMKIATBOJ-UHFFFAOYSA-N 0.000 claims 2
- 229940124530 sulfonamide Drugs 0.000 claims 2
- BHAJCEWFKZUIKQ-UHFFFAOYSA-N 2-[4-(2-hydroxyethoxy)-3,5-dimethylphenyl]-5,7-dimethoxy-1h-pyrido[2,3-d]pyrimidin-4-one Chemical compound N=1C(OC)=CC(OC)=C(C(N2)=O)C=1N=C2C1=CC(C)=C(OCCO)C(C)=C1 BHAJCEWFKZUIKQ-UHFFFAOYSA-N 0.000 claims 1
- PQVHQVOOKNUBMB-UHFFFAOYSA-N 2-[4-(2-hydroxyethoxy)-3,5-dimethylphenyl]-5-methoxy-1h-quinazolin-4-one Chemical compound N1C(=O)C=2C(OC)=CC=CC=2N=C1C1=CC(C)=C(OCCO)C(C)=C1 PQVHQVOOKNUBMB-UHFFFAOYSA-N 0.000 claims 1
- RJKSYSAMNAUDLG-UHFFFAOYSA-N 2-[4-(2-hydroxyethoxy)-3,5-dimethylphenyl]-6,7-dimethoxy-1h-quinazolin-4-one Chemical compound N1C(=O)C=2C=C(OC)C(OC)=CC=2N=C1C1=CC(C)=C(OCCO)C(C)=C1 RJKSYSAMNAUDLG-UHFFFAOYSA-N 0.000 claims 1
- NSYBXWYSRKNEDE-UHFFFAOYSA-N 2-[4-(2-hydroxyethoxy)-3,5-dimethylphenyl]-6-methoxy-1h-quinazolin-4-one Chemical compound N1C(=O)C2=CC(OC)=CC=C2N=C1C1=CC(C)=C(OCCO)C(C)=C1 NSYBXWYSRKNEDE-UHFFFAOYSA-N 0.000 claims 1
- SJASEOKEWBPIRK-UHFFFAOYSA-N 2-[4-(2-hydroxyethoxy)-3-methylphenyl]-5,7-dimethoxy-1h-quinazolin-4-one Chemical compound C=1C(OC)=CC(OC)=C(C(N2)=O)C=1N=C2C1=CC=C(OCCO)C(C)=C1 SJASEOKEWBPIRK-UHFFFAOYSA-N 0.000 claims 1
- XTOOVRVEMJAQFN-UHFFFAOYSA-N 2-[4-(4-hydroxybutoxy)-3,5-dimethylphenyl]-5,7-dimethoxy-1h-quinazolin-4-one Chemical compound C=1C(OC)=CC(OC)=C(C(N2)=O)C=1N=C2C1=CC(C)=C(OCCCCO)C(C)=C1 XTOOVRVEMJAQFN-UHFFFAOYSA-N 0.000 claims 1
- GIKJRBPNAUVPAL-UHFFFAOYSA-N 2-[4-(5,7-dimethoxy-4-oxo-1h-quinazolin-2-yl)-2,6-dimethylphenoxy]acetamide Chemical compound C=1C(OC)=CC(OC)=C(C(N2)=O)C=1N=C2C1=CC(C)=C(OCC(N)=O)C(C)=C1 GIKJRBPNAUVPAL-UHFFFAOYSA-N 0.000 claims 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims 1
- LPPHEORVQUBKAI-UHFFFAOYSA-N 3-[4-(2-hydroxy-2-methylpropoxy)-3,5-dimethylphenyl]-6,8-dimethoxy-2h-isoquinolin-1-one Chemical compound C=1C(OC)=CC(OC)=C(C(N2)=O)C=1C=C2C1=CC(C)=C(OCC(C)(C)O)C(C)=C1 LPPHEORVQUBKAI-UHFFFAOYSA-N 0.000 claims 1
- LFUOKUQHDNOIFT-UHFFFAOYSA-N 5,7-dichloro-2-[4-(2-hydroxyethoxy)-3,5-dimethylphenyl]-1h-quinazolin-4-one Chemical compound CC1=C(OCCO)C(C)=CC(C=2NC(=O)C3=C(Cl)C=C(Cl)C=C3N=2)=C1 LFUOKUQHDNOIFT-UHFFFAOYSA-N 0.000 claims 1
- YOHOTAMJRCWPER-UHFFFAOYSA-N 5,7-dimethoxy-2-(4-methoxy-3,5-dimethylphenyl)-1h-quinazolin-4-one Chemical compound C=1C(OC)=CC(OC)=C(C(N2)=O)C=1N=C2C1=CC(C)=C(OC)C(C)=C1 YOHOTAMJRCWPER-UHFFFAOYSA-N 0.000 claims 1
- COODZPZBQVVMAI-UHFFFAOYSA-N 5,7-dimethoxy-2-(4-methoxyphenyl)-1h-quinazolin-4-one Chemical compound C1=CC(OC)=CC=C1C1=NC2=CC(OC)=CC(OC)=C2C(=O)N1 COODZPZBQVVMAI-UHFFFAOYSA-N 0.000 claims 1
- AOJDYFWLCVYXPC-UHFFFAOYSA-N 5,7-dimethoxy-2-[4-methoxy-3-(morpholin-4-ylmethyl)phenyl]-1h-quinazolin-4-one Chemical compound C=1C(OC)=CC(OC)=C(C(N2)=O)C=1N=C2C(C=1)=CC=C(OC)C=1CN1CCOCC1 AOJDYFWLCVYXPC-UHFFFAOYSA-N 0.000 claims 1
- JWSHPKBSBZOEHQ-UHFFFAOYSA-N CC(=O)NCCOC(C(=O)N(C)CCO)OCCN(C)C Chemical compound CC(=O)NCCOC(C(=O)N(C)CCO)OCCN(C)C JWSHPKBSBZOEHQ-UHFFFAOYSA-N 0.000 claims 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- NETXMUIMUZJUTB-UHFFFAOYSA-N apabetalone Chemical compound C=1C(OC)=CC(OC)=C(C(N2)=O)C=1N=C2C1=CC(C)=C(OCCO)C(C)=C1 NETXMUIMUZJUTB-UHFFFAOYSA-N 0.000 claims 1
- 125000001246 bromo group Chemical group Br* 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002526 effect on cardiovascular system Effects 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 125000005343 heterocyclic alkyl group Chemical group 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 1
- RHHHGOZXDBLBFM-UHFFFAOYSA-N n-[2-[4-(2-hydroxyethoxy)-3,5-dimethylphenyl]-4-oxo-1h-quinazolin-6-yl]acetamide Chemical compound N1C(=O)C2=CC(NC(=O)C)=CC=C2N=C1C1=CC(C)=C(OCCO)C(C)=C1 RHHHGOZXDBLBFM-UHFFFAOYSA-N 0.000 claims 1
- QFZHJVFIABNVNU-UHFFFAOYSA-N n-[2-[4-(5,7-dimethoxy-4-oxo-1h-pyrido[2,3-d]pyrimidin-2-yl)-2,6-dimethylphenoxy]ethyl]acetamide Chemical compound N=1C(OC)=CC(OC)=C(C(N2)=O)C=1N=C2C1=CC(C)=C(OCCNC(C)=O)C(C)=C1 QFZHJVFIABNVNU-UHFFFAOYSA-N 0.000 claims 1
- ITRVWWNOGMNDNQ-UHFFFAOYSA-N n-[2-[4-(5,7-dimethoxy-4-oxo-1h-quinazolin-2-yl)-2,6-dimethylphenoxy]ethyl]-2-methylpropanamide Chemical compound C=1C(OC)=CC(OC)=C(C(N2)=O)C=1N=C2C1=CC(C)=C(OCCNC(=O)C(C)C)C(C)=C1 ITRVWWNOGMNDNQ-UHFFFAOYSA-N 0.000 claims 1
- PFHMVLYQAPTQRQ-UHFFFAOYSA-N n-[2-[4-(5,7-dimethoxy-4-oxo-1h-quinazolin-2-yl)-2,6-dimethylphenoxy]ethyl]-4-methoxybenzamide Chemical compound C1=CC(OC)=CC=C1C(=O)NCCOC1=C(C)C=C(C=2NC(=O)C3=C(OC)C=C(OC)C=C3N=2)C=C1C PFHMVLYQAPTQRQ-UHFFFAOYSA-N 0.000 claims 1
- JPXFKHCUTSMVGP-UHFFFAOYSA-N n-[2-[4-(5,7-dimethoxy-4-oxo-1h-quinazolin-2-yl)-2,6-dimethylphenoxy]ethyl]acetamide Chemical compound C=1C(OC)=CC(OC)=C(C(N2)=O)C=1N=C2C1=CC(C)=C(OCCNC(C)=O)C(C)=C1 JPXFKHCUTSMVGP-UHFFFAOYSA-N 0.000 claims 1
- PIRVGPWBOGNYAH-UHFFFAOYSA-N n-[2-[4-(5,7-dimethoxy-4-oxo-1h-quinazolin-2-yl)-2,6-dimethylphenoxy]ethyl]methanesulfonamide Chemical compound C=1C(OC)=CC(OC)=C(C(N2)=O)C=1N=C2C1=CC(C)=C(OCCNS(C)(=O)=O)C(C)=C1 PIRVGPWBOGNYAH-UHFFFAOYSA-N 0.000 claims 1
- YVVMUNNSVSVEEV-UHFFFAOYSA-N n-[2-[4-(5,7-dimethoxy-4-oxo-1h-quinazolin-2-yl)-2-methylphenoxy]ethyl]-2-methylpropanamide Chemical compound C=1C(OC)=CC(OC)=C(C(N2)=O)C=1N=C2C1=CC=C(OCCNC(=O)C(C)C)C(C)=C1 YVVMUNNSVSVEEV-UHFFFAOYSA-N 0.000 claims 1
- STAOOJVYTOKHDK-UHFFFAOYSA-N n-[2-[4-(5,7-dimethoxy-4-oxo-1h-quinazolin-2-yl)-2-methylphenoxy]ethyl]methanesulfonamide Chemical compound C=1C(OC)=CC(OC)=C(C(N2)=O)C=1N=C2C1=CC=C(OCCNS(C)(=O)=O)C(C)=C1 STAOOJVYTOKHDK-UHFFFAOYSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17162009P | 2009-04-22 | 2009-04-22 | |
| US61/171,620 | 2009-04-22 | ||
| PCT/US2010/031870 WO2010123975A1 (en) | 2009-04-22 | 2010-04-21 | Novel anti-inflammatory agents |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012524794A JP2012524794A (ja) | 2012-10-18 |
| JP2012524794A5 true JP2012524794A5 (enExample) | 2013-06-13 |
| JP5813626B2 JP5813626B2 (ja) | 2015-11-17 |
Family
ID=42236704
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012507341A Expired - Fee Related JP5813626B2 (ja) | 2009-04-22 | 2010-04-21 | 新規抗炎症剤 |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US9757368B2 (enExample) |
| EP (2) | EP3431086B1 (enExample) |
| JP (1) | JP5813626B2 (enExample) |
| KR (4) | KR101892987B1 (enExample) |
| CN (2) | CN102458405B (enExample) |
| AU (1) | AU2010239266B2 (enExample) |
| BR (1) | BRPI1014956B8 (enExample) |
| CA (1) | CA2759241C (enExample) |
| DK (1) | DK2421533T3 (enExample) |
| ES (2) | ES2821018T3 (enExample) |
| HR (1) | HRP20182200T1 (enExample) |
| IL (2) | IL215799A (enExample) |
| LT (1) | LT2421533T (enExample) |
| MX (2) | MX374414B (enExample) |
| NZ (1) | NZ596117A (enExample) |
| PL (1) | PL2421533T3 (enExample) |
| PT (1) | PT2421533T (enExample) |
| SI (1) | SI2421533T1 (enExample) |
| TR (1) | TR201818390T4 (enExample) |
| WO (1) | WO2010123975A1 (enExample) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1909788A2 (en) * | 2005-07-29 | 2008-04-16 | Resverlogix Corp. | Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices |
| SI2118074T1 (sl) | 2007-02-01 | 2014-05-30 | Resverlogix Corp. | Spojine za preprečevanje in zdravljenje kardiovaskularnih bolezni |
| EP2344502A2 (en) * | 2008-10-22 | 2011-07-20 | F. Hoffmann-La Roche AG | Pyrimidinyl pyridone inhibitors of jnk |
| NZ594332A (en) | 2009-01-08 | 2013-09-27 | Resverlogix Corp | Compounds for the prevention and treatment of cardiovascular disease |
| CN105859639A (zh) | 2009-03-18 | 2016-08-17 | 雷斯韦洛吉克斯公司 | 新的抗炎剂 |
| ITMI20100984A1 (it) * | 2010-05-31 | 2011-12-01 | Dipharma Francis Srl | Procedimento per la preparazione di ossadiazoli |
| WO2013033269A1 (en) | 2011-08-29 | 2013-03-07 | Coferon, Inc. | Bioorthogonal monomers capable of dimerizing and targeting bromodomains and methods of using same |
| WO2013033270A2 (en) | 2011-08-29 | 2013-03-07 | Coferon, Inc. | Bromodomain ligands capable of dimerizing in an aqueous solution, and methods of using same |
| US8710064B2 (en) * | 2011-10-20 | 2014-04-29 | China Medical University | 2-aryl-4-quinazolinones and their pharmaceutical compositions |
| AU2012330885B2 (en) | 2011-11-01 | 2016-10-06 | Resverlogix Corp. | Oral immediate release formulations for substituted quinazolinones |
| MX346147B (es) | 2012-03-07 | 2017-03-09 | Inst Of Cancer Research: Royal Cancer Hospital (The) | Compuestos de 3-aril-5-substituido-isoquinolin-1-ona y su uso terapeutico. |
| US20130281398A1 (en) * | 2012-04-19 | 2013-10-24 | Rvx Therapeutics Inc. | Treatment of diseases by epigenetic regulation |
| US20130281397A1 (en) * | 2012-04-19 | 2013-10-24 | Rvx Therapeutics Inc. | Treatment of diseases by epigenetic regulation |
| US20130281399A1 (en) * | 2012-04-19 | 2013-10-24 | Rvx Therapeutics Inc. | Treatment of diseases by epigenetic regulation |
| DK2906531T3 (en) | 2012-10-15 | 2018-02-05 | Resverlogix Corp | APPLICABLE COMPOUNDS IN THE SYNTHESIS OF BENZAMIDE COMPOUNDS |
| TWI692469B (zh) | 2012-11-09 | 2020-05-01 | 南韓商Ｌｇ化學股份有限公司 | Ｇｐｒ４０受體促效劑，製造該促效劑的方法以及含有該促效劑作爲活性劑的醫藥組成物 |
| US9765039B2 (en) | 2012-11-21 | 2017-09-19 | Zenith Epigenetics Ltd. | Biaryl derivatives as bromodomain inhibitors |
| US9073878B2 (en) | 2012-11-21 | 2015-07-07 | Zenith Epigenetics Corp. | Cyclic amines as bromodomain inhibitors |
| CA2895905A1 (en) | 2012-12-21 | 2014-06-26 | Zenith Epigenetics Corp. | Novel heterocyclic compounds as bromodomain inhibitors |
| RU2654483C2 (ru) | 2013-02-20 | 2018-05-21 | ЭлДжи КЕМ, ЛТД. | Агонисты рецептора сфингозин-1-фосфата, способы их получения и фармацевтические композиции, содержащие эти соединения в качестве активного средства |
| AU2014249192B2 (en) | 2013-03-11 | 2017-12-21 | The Regents Of The University Of Michigan | BET bromodomain inhibitors and therapeutic methods using the same |
| WO2015004533A2 (en) | 2013-06-21 | 2015-01-15 | Zenith Epigenetics Corp. | Novel substituted bicyclic compounds as bromodomain inhibitors |
| PL3010503T3 (pl) | 2013-06-21 | 2020-08-24 | Zenith Epigenetics Ltd. | Nowe bicykliczne inhibitory bromodomen |
| EP3027604B1 (en) | 2013-07-31 | 2019-02-20 | Zenith Epigenetics Ltd. | Novel quinazolinones as bromodomain inhibitors |
| JP6456392B2 (ja) | 2013-09-11 | 2019-01-23 | インスティチュート オブ キャンサー リサーチ：ロイヤル キャンサー ホスピタル | ３−アリール−５−置換イソキノリン−１−オン化合物及びその治療的使用 |
| CN103601675B (zh) * | 2013-10-08 | 2015-10-28 | 南京复兴生物科技有限公司 | 一种5-氨甲基烟酸的制备方法 |
| CA2940554A1 (en) | 2014-02-28 | 2015-09-03 | The Regents Of The University Of Michigan | 9h-pyrimido[4,5-b]indoles and related analogs as bet bromodomain inhibitors |
| US10710992B2 (en) | 2014-12-01 | 2020-07-14 | Zenith Epigenetics Ltd. | Substituted pyridinones as bromodomain inhibitors |
| EP3227280B1 (en) | 2014-12-01 | 2019-04-24 | Zenith Epigenetics Ltd. | Substituted pyridines as bromodomain inhibitors |
| CN107207474B (zh) | 2014-12-11 | 2021-05-07 | 恒翼生物医药科技(上海)有限公司 | 被取代的杂环作为溴结构域抑制剂 |
| US10231953B2 (en) | 2014-12-17 | 2019-03-19 | Zenith Epigenetics Ltd. | Inhibitors of bromodomains |
| US10307407B2 (en) | 2015-02-27 | 2019-06-04 | The Regents Of The University Of Michigan | 9H-pyrimido [4,5-B] indoles as BET bromodomain inhibitors |
| JO3789B1 (ar) | 2015-03-13 | 2021-01-31 | Resverlogix Corp | التراكيب والوسائل العلاجية المعتمدة لمعالجة الامراض المتعلقة بالمتممة |
| WO2016196065A1 (en) | 2015-05-29 | 2016-12-08 | Genentech, Inc. | Methods and compositions for assessing responsiveness of cancers to bet inhibitors |
| WO2017041701A1 (zh) * | 2015-09-07 | 2017-03-16 | 浙江华海药业股份有限公司 | 可释放一氧化氮的前药分子 |
| CN109071562B (zh) | 2016-02-15 | 2022-03-22 | 密执安大学评议会 | 作为bet溴结构域抑制剂的稠合1,4-氧氮杂䓬和相关类似物 |
| SG11201808728QA (en) | 2016-04-06 | 2018-11-29 | Univ Michigan Regents | Mdm2 protein degraders |
| CA3020281A1 (en) | 2016-04-06 | 2017-10-12 | The Regents Of The University Of Michigan | Monofunctional intermediates for ligand-dependent target protein degradation |
| UA123168C2 (uk) | 2016-04-12 | 2021-02-24 | Дзе Ріджентс Оф Дзе Юніверсіті Оф Мічіган | Деструктори білка вет |
| US10975093B2 (en) | 2016-09-13 | 2021-04-13 | The Regents Of The University Of Michigan | Fused 1,4-diazepines as BET protein degraders |
| EP3512855B1 (en) | 2016-09-13 | 2022-07-27 | The Regents of the University of Michigan | Fused 1,4-oxazepines as bet protein degraders |
| WO2018144789A1 (en) | 2017-02-03 | 2018-08-09 | The Regents Of The University Of Michigan | Fused 1,4-diazepines as bet bromodomain inhibitors |
| CN108069954B (zh) * | 2017-03-03 | 2018-11-23 | 上海华汇拓医药科技有限公司 | 含no供体的喹唑啉酮化合物 |
| US11992495B2 (en) | 2017-06-23 | 2024-05-28 | The Regents Of The University Of California | Enhancing GABA's ability to modulate immune responses |
| US11267822B2 (en) | 2017-09-13 | 2022-03-08 | The Regents Of The University Of Michigan | BET bromodomain protein degraders with cleavable linkers |
| CN108484510B (zh) * | 2018-05-18 | 2020-05-05 | 东南大学 | 一种基于brd4抑制剂rvx-208的衍生物及其制备方法和应用 |
| WO2021257863A1 (en) | 2020-06-19 | 2021-12-23 | Incyte Corporation | Pyrrolotriazine compounds as jak2 v617f inhibitors |
| US11691971B2 (en) | 2020-06-19 | 2023-07-04 | Incyte Corporation | Naphthyridinone compounds as JAK2 V617F inhibitors |
| HRP20250814T1 (hr) | 2020-07-02 | 2025-09-12 | Incyte Corporation | Spojevi tricikličke uree kao jak2 v617f inhibitori |
| US11767323B2 (en) | 2020-07-02 | 2023-09-26 | Incyte Corporation | Tricyclic pyridone compounds as JAK2 V617F inhibitors |
| US11661422B2 (en) | 2020-08-27 | 2023-05-30 | Incyte Corporation | Tricyclic urea compounds as JAK2 V617F inhibitors |
| WO2022140231A1 (en) | 2020-12-21 | 2022-06-30 | Incyte Corporation | Deazaguaine compounds as jak2 v617f inhibitors |
| CA3211748A1 (en) | 2021-02-25 | 2022-09-01 | Incyte Corporation | Spirocyclic lactams as jak2 v617f inhibitors |
| CN115710202B (zh) * | 2021-08-23 | 2024-05-03 | 江西同和药业股份有限公司 | 一种阿帕他酮关键中间体的制备方法及其应用 |
| CN113845484B (zh) * | 2021-09-07 | 2023-06-30 | 四川大学 | 喹唑啉类小分子抑制剂及其在抗肿瘤药物中的应用 |
| IL315647A (en) | 2022-03-17 | 2024-11-01 | Incyte Corp | Tricyclic urea compounds as Jak2 and 617f inhibitors |
| KR20240045472A (ko) * | 2022-09-30 | 2024-04-08 | 주식회사 베노바이오 | 퀴나졸린염 화합물을 포함하는 관절염 치료용 조성물 및 이의 제조 방법 |
Family Cites Families (234)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2065593A (en) | 1936-12-29 | Water-soluble diazoimino com | ||
| FR472489A (fr) | 1914-02-20 | 1914-12-08 | Stas Motor Ges M B H | Bague de garniture métallique pour pistons |
| US2065900A (en) | 1935-03-23 | 1936-12-29 | Gen Aniline Works Inc | Dihydroxystilbene-dicarboxylic acid and a process of preparing it |
| FR803619A (fr) | 1935-03-23 | 1936-10-05 | Ig Farbenindustrie Ag | Acide du type dihydroxystilbène-dicarboxylique et son procédé de préparation |
| DE637259C (de) | 1935-03-24 | 1936-10-27 | I G Farbenindustrie Akt Ges | Verfahren zur Darstellung einer Dioxystilbendicarbonsaeure |
| FR803201A (fr) | 1935-07-08 | 1936-09-25 | Ste Ind Chim Bale | Préparation d'acides sulfoniques |
| US2071329A (en) | 1935-08-22 | 1937-02-23 | Solvay Process Co | Method of recovering phthalic anhydride |
| DE652772C (de) | 1935-11-07 | 1937-11-08 | I G Farbenindustrie Akt Ges | Verfahren zur Herstellung von N-Dihydroazinen der Anthrachinonreihe |
| GB728767A (en) | 1951-10-12 | 1955-04-27 | Wander Ag Dr A | 2-substituted chromone compounds, and a method of making same |
| US3251837A (en) | 1962-09-14 | 1966-05-17 | Pfizer & Co C | Derivatives of 1, 2, 4-benzothiadiazine-1, 1-dioxides |
| GB1179019A (en) | 1967-05-23 | 1970-01-28 | Produits Chimique Soc Et | Polynicotinic Esters of Flavonoids |
| FR6928M (enExample) | 1967-11-24 | 1969-05-05 | ||
| US3600394A (en) | 1968-05-17 | 1971-08-17 | Searle & Co | 2-aminoalkyl-3-arylisocarbostyrils |
| US3930024A (en) | 1969-09-02 | 1975-12-30 | Parke Davis & Co | Pharmaceutical compositions and methods |
| US3773946A (en) | 1969-09-02 | 1973-11-20 | Parke Davis & Co | Triglyceride-lowering compositions and methods |
| DE2349024A1 (de) | 1973-09-26 | 1975-04-10 | Schering Ag | 6beta,7beta-epoxy-1alpha,2alphamethylen-d-homo-4-pregnen-3,20-dione |
| IT1050750B (it) | 1975-12-05 | 1981-03-20 | Erba Carlo Spa | Derivati della 3.4 di idro chinazolina |
| US4159330A (en) | 1976-11-02 | 1979-06-26 | Carlo Erba S.P.A. | 2-Disubstituted phenyl-3,4-dihydro-4-oxo-quinazoline derivatives and process for their preparation |
| US5098903A (en) | 1980-03-07 | 1992-03-24 | Board Of Regents Of The University Of Oklahoma | Diphenylcyclopropyl analogs as antiestrogenic and antitumor agents |
| IL64542A0 (en) | 1981-12-15 | 1982-03-31 | Yissum Res Dev Co | Long-chain alpha,omega-dicarboxylic acids and derivatives thereof and pharmaceutical compositions containing them |
| JPS60136512A (ja) | 1983-12-26 | 1985-07-20 | Eisai Co Ltd | 脂質代謝改善剤 |
| DE3423166A1 (de) | 1984-06-22 | 1986-01-02 | Epis S.A., Zug | Alpha-, omega-dicarbonsaeuren, verfahren zu ihrer herstellung und arzneimittel, die diese verbindungen enthalten |
| DE3579888D1 (de) | 1984-11-08 | 1990-10-31 | Sumitomo Pharma | Carbapenemverbindungen und deren herstellung. |
| DE3515882A1 (de) | 1985-05-03 | 1986-11-06 | Dr. Karl Thomae Gmbh, 7950 Biberach | Arzneimittel, enthaltend pyridinone mit antithrombotischen wirkungen und verfahren zu ihrer herstellung |
| DE3532279A1 (de) | 1985-09-11 | 1987-03-12 | Bayer Ag | 1,4-benzoxathiin-derivate |
| DE3601417A1 (de) | 1986-01-20 | 1987-07-23 | Nattermann A & Cie | 2'-alkyl-(alkenyl-) substituierte quercetine |
| US4825005A (en) | 1986-08-29 | 1989-04-25 | Ciba-Geigy Corporation | Process for the preparation of aromatic ether and thioether compounds |
| ES2053508T3 (es) | 1986-11-24 | 1994-08-01 | Fujisawa Pharmaceutical Co | Compuestos de acidos 3-pirrolidinil-tio-1-azabiciclo(3.2.0)hept-2-eno-2-carboxilicos. |
| GB8804058D0 (en) | 1988-02-22 | 1988-03-23 | Fujisawa Pharmaceutical Co | 3-alkenyl-1-azabicyclo(3 2 0)hept-2-ene-2-carboxylic acid compounds |
| US4925838A (en) | 1988-03-18 | 1990-05-15 | Fujisawa Pharmaceutical Company, Ltd. | 3-pyrrolidinylthio-1-azabicyclo[3.2.0]-hept-2-ene-2-carboxylic acid compounds |
| US4963544A (en) | 1988-05-23 | 1990-10-16 | Fujisawa Pharmaceutical Company, Ltd. | 3-pyrrolidinylthio-1-azabicyclo[3.2.0]-hept-2-ene-2-carboxylic acid compounds |
| GB8926981D0 (en) | 1988-12-23 | 1990-01-17 | Ici Plc | Heterocyclic derivatives |
| KR920701167A (ko) | 1989-07-07 | 1992-08-11 | 에릭 에스. 딕커 | 약제학적 활성 화합물 |
| FR2649612A1 (fr) | 1989-07-17 | 1991-01-18 | Rhone Poulenc Sante | Medicaments a base de derives de 1h-benzoxadiazine-4,1,2 nouveaux derives et leurs procedes de preparation |
| IE64358B1 (en) | 1989-07-18 | 1995-07-26 | Ici Plc | Diaryl ether heterocycles |
| GB9018134D0 (en) | 1989-09-29 | 1990-10-03 | Ici Plc | Heterocyclic derivatives |
| DE69125099T2 (de) | 1990-06-05 | 1997-06-19 | Toray Industries, Inc., Tokio/Tokyo | Indolderivate |
| JP2999579B2 (ja) | 1990-07-18 | 2000-01-17 | 武田薬品工業株式会社 | Ｄｎａおよびその用途 |
| GB9025832D0 (en) | 1990-11-28 | 1991-01-09 | Ashwell Geoffrey J | Novel films for nonlinear optical applications |
| IE913866A1 (en) | 1990-11-28 | 1992-06-03 | Ici Plc | Aryl derivatives |
| US5126351A (en) | 1991-01-24 | 1992-06-30 | Glaxo Inc. | Antitumor compounds |
| MX9200299A (es) | 1991-02-07 | 1992-12-01 | Roussel Uclaf | Nuevos derivados biciclicos nitrogenados, su procedimiento de preparacion los nuevos compuestos intermedios obtenidos su aplicacion como medicamentos y las composiciones farmaceuticas que los contienen. |
| JPH06504791A (ja) | 1991-04-10 | 1994-06-02 | オクタマー，インコーポレイティド | レトロウィルス複製の阻害のための方法 |
| ES2108120T3 (es) | 1991-05-10 | 1997-12-16 | Rhone Poulenc Rorer Int | Compuestos bis arilicos y heteroarilicos mono- y biciclicos que inhiben tirosina quinasa receptora de egf y/o pdgf. |
| US5480883A (en) | 1991-05-10 | 1996-01-02 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| US5124337A (en) | 1991-05-20 | 1992-06-23 | Schering Corporation | N-acyl-tetrahydroisoquinolines as inhibitors of acyl-coenzyme a:cholesterol acyl transferase |
| US5223506A (en) | 1991-06-04 | 1993-06-29 | Glaxo Inc. | Cyclic antitumor compounds |
| PT100905A (pt) | 1991-09-30 | 1994-02-28 | Eisai Co Ltd | Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem |
| US5250679A (en) | 1991-10-18 | 1993-10-05 | Genentech, Inc. | Nonpeptidyl platelet aggregation inhibitors having specificity for the GPIIb III.sub. receptor |
| GB9126260D0 (en) | 1991-12-11 | 1992-02-12 | Pfizer Ltd | Therapeutic agents |
| US5474994A (en) | 1992-05-26 | 1995-12-12 | Recordati S.A., Chemical And Pharmaceutical Company | Bicyclic heterocyclic derivatives having α1 -adrenergic and 5HT1A |
| FR2689127B1 (fr) | 1992-03-31 | 1994-05-06 | Adir Cie | Nouvelles 3', 5' -ditertbutyl-4'-hydroxy flavones, leur procede de preparation et les compositions pharmaceutiques les renfermant. |
| US7655699B1 (en) * | 1992-04-22 | 2010-02-02 | Eisai Inc. | Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors |
| DE4215587A1 (de) | 1992-05-12 | 1993-11-18 | Bayer Ag | Sulfonylbenzyl-substituierte Benzo- und Pyridopyridone |
| DE4215588A1 (de) | 1992-05-12 | 1993-11-18 | Bayer Ag | Biphenylmethyl-substituierte Pyridone |
| GB9218334D0 (en) | 1992-08-28 | 1992-10-14 | Ici Plc | Heterocyclic compounds |
| JPH0680656A (ja) | 1992-09-03 | 1994-03-22 | Mitsui Petrochem Ind Ltd | 光学活性エポキシドの製造方法 |
| AU5850894A (en) | 1992-12-23 | 1994-07-19 | Procept, Inc. | Novel agents for inhibition of hiv infectivity and use therefor |
| JPH0741442A (ja) | 1993-05-21 | 1995-02-10 | Sumitomo Chem Co Ltd | アセチレンアルコール誘導体およびその製造法 |
| JPH0761942A (ja) | 1993-06-17 | 1995-03-07 | Sumitomo Chem Co Ltd | フェノール誘導体およびその製造法 |
| JPH0725761A (ja) | 1993-07-09 | 1995-01-27 | Kureha Chem Ind Co Ltd | 軟骨保護剤 |
| WO1995003277A1 (en) | 1993-07-23 | 1995-02-02 | Zaidan Hojin Biseibutsu Kagaku Kenkyukai | Novel pyrrolidine derivative |
| US5707547A (en) | 1993-08-03 | 1998-01-13 | Sumitomo Chemical Company, Limited | Trans-olefin compounds, method for production thereof, liquid crystal composition containing the same as active ingredient, and liquid crystal element using said composition |
| JPH07118241A (ja) | 1993-09-01 | 1995-05-09 | Sumitomo Chem Co Ltd | フェノール誘導体およびその製造法 |
| JPH07179380A (ja) | 1993-12-22 | 1995-07-18 | Sumitomo Chem Co Ltd | アルコール誘導体およびその製造法 |
| JPH07233109A (ja) | 1994-02-24 | 1995-09-05 | Sumitomo Chem Co Ltd | 光学活性なアルコール誘導体およびその製造法 |
| US5707987A (en) | 1994-02-25 | 1998-01-13 | Banyu Pharmaceutical Co., Ltd. | Carbapenem derivatives |
| KR100233703B1 (ko) | 1994-03-08 | 1999-12-01 | 오츠까 요시미쯔 | 포스폰산 디에스테르 유도체 |
| JPH07247289A (ja) | 1994-03-11 | 1995-09-26 | Mitsui Petrochem Ind Ltd | クロメンオキシド類の製造方法 |
| FR2718329B1 (fr) | 1994-03-21 | 2002-09-20 | Rhone Poulenc Rorer Sa | Lapin transgénique sensibilisé aux dyslipoprotéinémies. |
| US6048903A (en) | 1994-05-03 | 2000-04-11 | Robert Toppo | Treatment for blood cholesterol with trans-resveratrol |
| US6168776B1 (en) | 1994-07-19 | 2001-01-02 | University Of Pittsburgh | Alkyl, alkenyl and alkynyl Chrysamine G derivatives for the antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition |
| GB2292149A (en) | 1994-08-09 | 1996-02-14 | Ferring Res Ltd | Peptide inhibitors of pro-interleukin-1beta converting enzyme |
| JP3702493B2 (ja) | 1994-08-12 | 2005-10-05 | 大正製薬株式会社 | キナゾリン−４（３ｈ）−オン誘導体 |
| ES2146782T3 (es) | 1994-11-14 | 2000-08-16 | Warner Lambert Co | 6-aril-pirido(2,3-d)pirimidinas y naftiridinas para la inhibicion de la proliferacion celular inducida por la proteina tirosina quinasa. |
| IL115256A0 (en) | 1994-11-14 | 1995-12-31 | Warner Lambert Co | 6-Aryl pyrido (2,3-d) pyrimidines and naphthyridines and their use |
| US5446071A (en) | 1994-11-18 | 1995-08-29 | Eli Lilly And Company | Methods for lowering serum cholesterol |
| JP4140981B2 (ja) | 1994-12-26 | 2008-08-27 | 東菱薬品工業株式会社 | 再狭窄症及び動脈硬化症治療薬 |
| US5648387A (en) | 1995-03-24 | 1997-07-15 | Warner-Lambert Company | Carboxyalkylethers, formulations, and treatment of vascular diseases |
| AU5259296A (en) | 1995-04-07 | 1996-10-23 | Warner-Lambert Company | Flavones and coumarins as agents for the treatment of athero sclerosis |
| ES2180702T3 (es) | 1995-06-07 | 2003-02-16 | Lilly Co Eli | Tratamiento de patologias por la induccion del factor de transcripcion bef-1. |
| WO1997008153A1 (en) | 1995-08-30 | 1997-03-06 | Otsuka Pharmaceutical Factory, Inc. | Process for producing quinazolin-4-one derivatives |
| US5783577A (en) | 1995-09-15 | 1998-07-21 | Trega Biosciences, Inc. | Synthesis of quinazolinone libraries and derivatives thereof |
| AU4858596A (en) | 1995-09-15 | 1997-04-01 | Torrey Pines Institute For Molecular Studies | Synthesis of quinazolinone libraries |
| PL327617A1 (en) | 1995-10-23 | 1998-12-21 | Zymogenetics Inc | Compositions for and methods of treating osseous insufficiency |
| RU2135494C1 (ru) | 1995-12-01 | 1999-08-27 | Санкио Компани Лимитед | Гетероциклические соединения и композиция на их основе, проявляющая антагонистическое действие в отношении рецепторов тахикинина |
| US5756736A (en) | 1996-01-26 | 1998-05-26 | Syntex (U.S.A.) Inc. | Process for preparing a 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol derivative |
| US5739330A (en) | 1996-02-05 | 1998-04-14 | Hoechst Celanese Corporation | Process for preparing quinazolones |
| WO1997028118A1 (en) | 1996-02-05 | 1997-08-07 | Hoechst Celanese Corporation | Process for preparing anthranilic acids |
| US5763608A (en) | 1996-02-05 | 1998-06-09 | Hoechst Celanese Corporation | Process for preparing pyrimidine derivatives |
| HUP9900413A3 (en) | 1996-02-12 | 2002-02-28 | Univ Rutgers | Use of coralyne derivatives, new coralyne derivatives and use thereof, pharmaceutical compositions containing these new coralyne derivatives |
| KR20000022040A (ko) | 1996-06-20 | 2000-04-25 | 보오드 오브 리젠츠, 더 유니버시티 오브 텍사스 시스템 | 약학적 활성 제제를 제공하기 위한 화합물, 방법 및 그의 용도 |
| US5854264A (en) | 1996-07-24 | 1998-12-29 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| KR100213895B1 (ko) | 1996-10-14 | 1999-08-02 | 박원훈 | 감귤류 과피 추출물, 이로부터 분리 정제된 헤스페리딘 또는 나린진을 포함하는 심혈관 질환 예방및 치료제 조성물 |
| DE19651099A1 (de) | 1996-12-09 | 1998-06-10 | Consortium Elektrochem Ind | Mehrkomponentensystem zum Verändern, Abbau oder Bleichen von Lignin, ligninhaltigen Materialien oder ähnlichen Stoffen sowie Verfahren zu seiner Anwendung |
| IL119971A (en) | 1997-01-07 | 2003-02-12 | Yissum Res Dev Co | Pharmaceutical compositions containing dicarboxylic acids and derivatives thereof and some novel dicarboxylic acids |
| JPH10287678A (ja) | 1997-04-11 | 1998-10-27 | Kyowa Hakko Kogyo Co Ltd | ピラノアジン誘導体 |
| AR012634A1 (es) | 1997-05-02 | 2000-11-08 | Sugen Inc | Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion |
| US5908861A (en) | 1997-05-13 | 1999-06-01 | Octamer, Inc. | Methods for treating inflammation and inflammatory disease using pADPRT inhibitors |
| JP4362638B2 (ja) | 1997-05-13 | 2009-11-11 | オクテイマー・インコーポレイテッド | ｐＡＤＰＲＴインヒビターを用いる炎症および炎症性疾患の処置法 |
| ATE222104T1 (de) | 1997-06-02 | 2002-08-15 | Janssen Pharmaceutica Nv | (imidazol-5-yl)methyl-2-quinolinone derivativen als inhibitoren von proliferation der glatten muskelzellen |
| IL121165A0 (en) | 1997-06-26 | 1997-11-20 | Yissum Res Dev Co | Pharmaceutical compositions containing carboxylic acids and derivatives thereof |
| CN1159302C (zh) | 1997-08-29 | 2004-07-28 | 武田舍林-普劳动物保健株式会社 | 三嗪衍生物,其制备及应用 |
| US6635642B1 (en) | 1997-09-03 | 2003-10-21 | Guilford Pharmaceuticals Inc. | PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same |
| US6239114B1 (en) | 1997-09-26 | 2001-05-29 | Kgk Synergize | Compositions and methods for treatment of neoplastic diseases with combinations of limonoids, flavonoids and tocotrienols |
| WO1999018077A1 (en) | 1997-10-02 | 1999-04-15 | Eisai Co., Ltd. | Fused pyridine derivatives |
| WO1999021548A1 (en) | 1997-10-28 | 1999-05-06 | Korea Institute Of Science And Technology | Naringin and naringenin as inhibitor of acyl coa-cholesterol-o-acyltransferase, inhibitor of macrophage-lipid complex accumulation on the arterial wall and preventive or treating agent for hepatic diseases |
| GB9725782D0 (en) | 1997-12-05 | 1998-02-04 | Pfizer Ltd | Therapeutic agents |
| DE19756388A1 (de) | 1997-12-18 | 1999-06-24 | Hoechst Marion Roussel De Gmbh | Substituierte 2-Aryl-4-amino-chinazoline |
| DK1049767T3 (da) | 1998-01-08 | 2005-09-19 | Aventis Pharma Inc | En transgen kanin, der udtrykker et funktionelt humant lipoprotein(A) |
| US6414037B1 (en) | 1998-01-09 | 2002-07-02 | Pharmascience | Pharmaceutical formulations of resveratrol and methods of use thereof |
| JP4124573B2 (ja) | 1998-03-17 | 2008-07-23 | 中外製薬株式会社 | Ｉｌ−６アンタゴニストを有効成分として含有する炎症性腸疾患の予防又は治療剤 |
| US6022901A (en) | 1998-05-13 | 2000-02-08 | Pharmascience Inc. | Administration of resveratrol to prevent or treat restenosis following coronary intervention |
| CA2341239C (en) | 1998-08-24 | 2011-01-04 | Chugai Seiyaku Kabushiki Kaisha | A preventive or therapeutic agent for pancreatitis comprising il-6 antagonist as an active ingredient |
| SE9802973D0 (sv) | 1998-09-03 | 1998-09-03 | Astra Ab | Immediate release tablet |
| AU5759899A (en) | 1998-09-24 | 2000-04-10 | Mitsubishi Chemical Corporation | Hydroxyflavone derivatives as tau protein kinase 1 inhibitors |
| CN1148188C (zh) | 1998-10-19 | 2004-05-05 | 卫材株式会社 | 镇痛剂 |
| CN1327384A (zh) | 1998-10-20 | 2001-12-19 | 韩国科学技术研究院 | 作为血浆高密度脂蛋白浓度增高剂的生物类黄酮 |
| US6433187B1 (en) | 1998-12-17 | 2002-08-13 | Tularik Inc. | Certain polycyclic compounds useful as tubulin-binding agents |
| US6291456B1 (en) | 1998-12-30 | 2001-09-18 | Signal Pharmaceuticals, Inc. | Compounds and methods for modulation of estrogen receptors |
| US6399633B1 (en) | 1999-02-01 | 2002-06-04 | Aventis Pharmaceuticals Inc. | Use of 4-H-1-benzopryan-4-one derivatives as inhibitors of smooth muscle cell proliferation |
| HUP0201067A3 (en) | 1999-03-15 | 2004-07-28 | Abbott Lab | 6-o-substituted macrolides having antibacterial activity, pharmaceutical compositions containing them, their use and process for preparation of the compounds |
| US6969720B2 (en) | 1999-03-17 | 2005-11-29 | Amr Technology, Inc. | Biaryl substituted purine derivatives as potent antiproliferative agents |
| US6054435A (en) | 1999-03-19 | 2000-04-25 | Abbott Laboratories | 6-O-substituted macrolides having antibacterial activity |
| RU2267484C2 (ru) | 1999-04-28 | 2006-01-10 | Авентис Фарма Дойчланд Гмбх | Производные диариловой кислоты и фармацевтическая композиция на их основе |
| US6835755B1 (en) | 1999-06-24 | 2004-12-28 | University Of Pretoria | Naphthoquinone derivatives and their use in the treatment and control of tuberculosis |
| DE19934799B4 (de) | 1999-07-28 | 2008-01-24 | Az Electronic Materials (Germany) Gmbh | Chiral-smektische Flüssigkristallmischung und ihre Verwendung in Aktivmatrix-Displays mit hohen Kontrastwerten |
| JP2001131151A (ja) | 1999-11-02 | 2001-05-15 | Shionogi & Co Ltd | オレフィン誘導体の新規用途 |
| JP5278983B2 (ja) | 1999-11-17 | 2013-09-04 | 塩野義製薬株式会社 | アミド化合物の新規用途 |
| ES2334635T3 (es) | 1999-12-06 | 2010-03-15 | Welichem Biotech Inc. | Polihidroxiestilbeno y oxidos de estilbeno como agentes antipsoriasicos e inhibidores de la proteina quinasa. |
| FR2804679B1 (fr) | 2000-02-07 | 2002-04-26 | Clariant France Sa | Nouveaux composes phenoliques derives des dialcoxyethanals, leur procede de preparation et leur application |
| JP2003522810A (ja) | 2000-02-17 | 2003-07-29 | アップルトン ペーパーズ インコーポレイテッド | アルコキシ又はアリルメトキシエタンの製造方法 |
| WO2001083456A1 (en) | 2000-04-27 | 2001-11-08 | Yamanouchi Pharmaceutical Co., Ltd. | Condensed heteroaryl derivatives |
| AU6118001A (en) | 2000-05-03 | 2001-11-12 | Tularik Inc | Combination therapeutic compositions and methods of use |
| US6548694B2 (en) | 2000-05-23 | 2003-04-15 | Hoffman-La Roche Inc. | N-(4-carbamimidoyl-phenyl)-glycine derivatives |
| JP2001335476A (ja) | 2000-05-29 | 2001-12-04 | Shionogi & Co Ltd | 三環化合物の新規用途 |
| US6479499B1 (en) | 2000-06-28 | 2002-11-12 | National Science Council | 2-phenyl-4-quinazolinone compounds, 2-phenyl-4-alkoxy-quinazoline compounds and their pharmaceutical compositions |
| JP2002047283A (ja) | 2000-07-04 | 2002-02-12 | Basf Ag | 新規フラボノイドおよびそれらの化粧用または皮膚科用製品における使用 |
| US6541522B2 (en) | 2000-08-16 | 2003-04-01 | Insmed Incorporated | Methods of using compositions containing hypotriglyceridemically active stilbenoids |
| CA2356544C (en) | 2000-10-03 | 2006-04-04 | Warner-Lambert Company | Pyridotriazines and pyridopyridazines |
| CN1478077A (zh) | 2000-10-05 | 2004-02-25 | ����ҩƷ��ҵ��ʽ���� | 作为apo b分泌抑制剂的苯甲酰胺化合物 |
| MXPA03003022A (es) | 2000-10-11 | 2003-07-14 | Esperion Therapeutics Inc | Compuestos de sulfuro y disulfuro y composiciones para el control del colesterol y usos relacionados. |
| CA2425678A1 (en) | 2000-10-11 | 2002-04-18 | Jean-Louis H. Dasseux | Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses |
| AU3238102A (en) | 2000-10-19 | 2002-04-29 | Merck & Co Inc | Estrogen receptor modulators |
| KR100846526B1 (ko) | 2000-11-30 | 2008-07-15 | 캐논 가부시끼가이샤 | 발광 소자 및 표시 장치 |
| CA2430951A1 (en) | 2000-12-07 | 2002-06-13 | Cv Therapeutics, Inc. | Substituted 1, 3, 5-triazines and pyrimidines as abca-1 elevating compounds against coronary artery disease or atherosclerosis |
| KR100472694B1 (ko) | 2000-12-30 | 2005-03-07 | 한국생명공학연구원 | 플라바논 유도체 및 이를 포함하는 혈중 지질 농도 관련질환의 예방 및 치료용 조성물 |
| JP2002249483A (ja) | 2001-02-21 | 2002-09-06 | Koei Chem Co Ltd | アリール置換複素環式化合物の製造法 |
| WO2002074307A1 (en) | 2001-03-16 | 2002-09-26 | Novogen Research Pty Ltd | Treatment of restenosis |
| EP1385501A2 (en) | 2001-04-11 | 2004-02-04 | Atherogenics, Inc. | Probucol monoesters and their use to increase plasma hdl cholesterol levels and improve hdl functionality |
| JP2004535411A (ja) | 2001-05-25 | 2004-11-25 | ブリストルーマイヤーズ スクイブ カンパニー | マトリックスメタロプロテナーゼ及び／またはＴＮＦ−α転換酵素（ＴＡＣＥ）の阻害剤としてのヒダントイン及び関連複素環化合物 |
| WO2003007959A1 (en) | 2001-07-16 | 2003-01-30 | Fujisawa Pharmaceutical Co., Ltd. | Quinoxaline derivatives which have parp inhibitory action |
| US7173128B2 (en) | 2001-08-13 | 2007-02-06 | Ciba Specialty Chemicals Corporation | Ultraviolet light absorbers |
| US20040248950A1 (en) | 2001-08-24 | 2004-12-09 | Natsuki Ishizuka | Apo ai expression accelerating agent |
| US7429593B2 (en) | 2001-09-14 | 2008-09-30 | Shionogi & Co., Ltd. | Utilities of amide compounds |
| US8124625B2 (en) | 2001-09-14 | 2012-02-28 | Shionogi & Co., Ltd. | Method of enhancing the expression of apolipoprotein AI using olefin derivatives |
| EP2168576A3 (en) | 2001-09-14 | 2010-05-26 | Shionogi & Co., Ltd. | Tricyclic compounds for treating dyslipidemia and arteriosclerotic diseases |
| US6835469B2 (en) | 2001-10-17 | 2004-12-28 | The University Of Southern California | Phosphorescent compounds and devices comprising the same |
| US7250512B2 (en) | 2001-11-07 | 2007-07-31 | E. I. Du Pont De Nemours And Company | Electroluminescent iridium compounds having red-orange or red emission and devices made with such compounds |
| US7166368B2 (en) | 2001-11-07 | 2007-01-23 | E. I. Du Pont De Nemours And Company | Electroluminescent platinum compounds and devices made with such compounds |
| US6541045B1 (en) | 2002-01-04 | 2003-04-01 | Nutraceutical Corporation | Herbal composition and method for combating inflammation |
| JP4389204B2 (ja) | 2002-01-28 | 2009-12-24 | 宇部興産株式会社 | キナゾリン−４−オン誘導体の製造方法 |
| MXPA04008680A (es) | 2002-02-19 | 2004-12-06 | Pharmacia Italia Spa | Derivados de pirazol triciclicos, procedimientos para su preparacion y su uso como agentes anti-tumorales. |
| GB0206033D0 (en) | 2002-03-14 | 2002-04-24 | Pfizer Ltd | Compounds useful in therapy |
| NZ556545A (en) | 2002-03-22 | 2009-03-31 | Novartis Ag | Combination comprising a beta-hydroxy-beta-methylglutaryl-co-enzyme-A reductase inhibitor and a glucagon-like peptide-1 agonist |
| MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
| TW200401770A (en) | 2002-06-18 | 2004-02-01 | Sankyo Co | Fused-ring pyrimidin-4(3H)-one derivatives, processes for the preparation and uses thereof |
| KR20040001144A (ko) | 2002-06-27 | 2004-01-07 | 김대경 | 신규한 적혈구 세포질형 포스포리파아제 에이 투 효소,그에 대한 항체, 이들의 용도 및 제조 방법 |
| US20050080021A1 (en) | 2002-08-15 | 2005-04-14 | Joseph Tucker | Nitric oxide donating derivatives of stilbenes, polyphenols and flavonoids for the treatment of cardiovascular disorders |
| US20050080024A1 (en) | 2002-08-15 | 2005-04-14 | Joseph Tucker | Nitric oxide donating derivatives for the treatment of cardiovascular disorders |
| US20040033480A1 (en) | 2002-08-15 | 2004-02-19 | Wong Norman C.W. | Use of resveratrol to regulate expression of apolipoprotein A1 |
| CA2495903A1 (en) | 2002-08-23 | 2004-03-04 | University Of Connecticut | Novel biphenyl and biphenyl-like cannabinoids |
| AU2003262946A1 (en) | 2002-08-30 | 2004-03-19 | Pharmacia And Upjohn Company | Method of preventing or treating atherosclerosis or restenosis |
| EP1407774A1 (en) | 2002-09-10 | 2004-04-14 | LION Bioscience AG | 2-Amino-4-quinazolinones as LXR nuclear receptor binding compounds |
| EP1398032A1 (en) | 2002-09-10 | 2004-03-17 | PheneX Pharmaceuticals AG | 4-Oxo-quinazolines as LXR nuclear receptor binding compounds |
| AU2003284001A1 (en) | 2002-10-07 | 2004-05-04 | Bristol-Myers Squibb Company | Triazolone and triazolethione derivatives |
| AU2003301662A1 (en) | 2002-10-21 | 2004-05-13 | Bristol-Myers Squibb Company | Quinazolinones and derivatives thereof as factor xa inhibitors |
| WO2004039795A2 (en) | 2002-10-29 | 2004-05-13 | Fujisawa Pharmaceutical Co., Ltd. | Amide compounds for the treatment of hyperlipidemia |
| EP1418164A1 (en) | 2002-11-07 | 2004-05-12 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | New stilbene derivatives and their use as aryl hydrocarbon receptor ligand antagonists |
| DE60327097D1 (de) | 2002-11-18 | 2009-05-20 | Hoffmann La Roche | Diazinopyrimidine und ihre verwendung als proteinkinaseinhibitoren |
| RU2342388C2 (ru) | 2002-11-22 | 2008-12-27 | Джапан Тобакко Инк. | Конденсированные бициклические азотсодержащие гетероциклы, обладающие dgat ингибирующим действием |
| ES2270154T3 (es) | 2002-12-13 | 2007-04-01 | F. Hoffmann-La Roche Ag | Derivados de 3h-quinazolin-4-ona. |
| ITRM20020629A1 (it) | 2002-12-19 | 2004-06-20 | Sigma Tau Ind Farmaceuti | Uso di acidi alfa-feniltiocarbossilici e alfa-fenilossicarbossilici ad attivita' ipoglicemizzante e/o ipolipidemizzante. |
| ES2361924T3 (es) | 2002-12-20 | 2011-06-24 | X-Ceptor Therapeutics, Inc. | Derivados de isoquinolinona y su uso como agentes terapéuticos. |
| JP2004203751A (ja) | 2002-12-24 | 2004-07-22 | Pfizer Inc | 置換６，６−ヘテロ二環式誘導体 |
| AU2003292625B2 (en) | 2002-12-26 | 2008-07-24 | Eisai R & D Management Co., Ltd. | Selective estrogen receptor modulators |
| WO2004065392A1 (en) | 2003-01-24 | 2004-08-05 | Smithkline Beecham Corporation | Condensed pyridines and pyrimidines and their use as alk-5 receptor ligands |
| WO2004072042A2 (en) | 2003-02-12 | 2004-08-26 | Carex S.A. | Quinoline derivative and their use for modulation of lxr activity |
| WO2004092154A1 (en) | 2003-04-03 | 2004-10-28 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of protein kinases |
| US7763627B2 (en) | 2003-04-09 | 2010-07-27 | Exelixis, Inc. | Tie-2 modulators and methods of use |
| JP2004307440A (ja) | 2003-04-10 | 2004-11-04 | Kyorin Pharmaceut Co Ltd | ２−アミノ‐１，３‐プロパンジオール誘導体とその付加塩 |
| ATE422895T1 (de) | 2003-04-16 | 2009-03-15 | Bristol Myers Squibb Co | Makrocyclische isochinolinpeptidinhibitoren des hepatitis-c-virus |
| CA2525383C (en) | 2003-06-06 | 2012-03-06 | Arexis Ab | Use of heterocyclic compounds as scce inhibitors |
| WO2004112710A2 (en) | 2003-06-17 | 2004-12-29 | Millennium Pharmaceuticals, Inc. | COMPOSITIONS AND METHODS FOR INHIBITING TGF-ß |
| EP1637523A4 (en) | 2003-06-18 | 2009-01-07 | Ube Industries | PROCESS FOR PRODUCING A PYRIMIDIN-4-ONE COMPOUND |
| US20050043300A1 (en) | 2003-08-14 | 2005-02-24 | Pfizer Inc. | Piperazine derivatives |
| MXPA06003838A (es) | 2003-10-10 | 2006-07-03 | Resverlogix Corp | Tratamiento de enfermedades asociadas con el elemento mejorador de egr-1. |
| WO2005042712A2 (en) | 2003-10-28 | 2005-05-12 | Reddy Us Therapeutics, Inc. | Heterocyclic compounds and methods of making and using thereof |
| CA2549641A1 (en) | 2003-12-19 | 2005-07-21 | Merck & Co., Inc. | Mitotic kinesin inhibitors |
| WO2005066162A1 (en) | 2003-12-23 | 2005-07-21 | Human Biomolecular Research Institute | Synthetic compounds and derivatives as modulators of smoking or nicotine ingestion and lung cancer |
| TW200536830A (en) | 2004-02-06 | 2005-11-16 | Chugai Pharmaceutical Co Ltd | 1-(2H)-isoquinolone derivative |
| JPWO2005115993A1 (ja) | 2004-05-31 | 2008-03-27 | 萬有製薬株式会社 | キナゾリン誘導体 |
| GB0512324D0 (en) | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
| WO2006012577A2 (en) | 2004-07-22 | 2006-02-02 | Bayer Pharmaceuticals Corporation | Quinazolinone derivatives useful for the regulation of glucose homeostasis and food intake |
| US20070218155A1 (en) | 2004-08-20 | 2007-09-20 | Kuhrts Eric H | Methods and compositions for treating dyslipidaemia |
| CA2584485C (en) | 2004-10-20 | 2013-12-31 | Resverlogix Corp. | Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases |
| US20080152595A1 (en) | 2004-11-24 | 2008-06-26 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse of orally administered pharmaceutical products |
| WO2006071095A1 (en) | 2004-12-31 | 2006-07-06 | Sk Chemicals Co., Ltd. | Quinazoline derivatives for the treatment and prevention of diabetes and obesity |
| CR9465A (es) | 2005-03-25 | 2008-06-19 | Surface Logix Inc | Compuestos mejorados farmacocineticamente |
| EP1909788A2 (en) * | 2005-07-29 | 2008-04-16 | Resverlogix Corp. | Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices |
| EP1944301A4 (en) | 2005-10-27 | 2012-01-04 | Msd Kk | NEW BENZOXATHIIN DERIVATIVES |
| US20070197509A1 (en) | 2005-12-21 | 2007-08-23 | Painceptor Pharma Corporation | Compositions and methods for modulating gated ion channels |
| EP1928425B1 (en) | 2006-05-12 | 2013-01-23 | Pharmathen S.A. | Pharmaceutical formulation containing fluvastatin |
| SI2118074T1 (sl) | 2007-02-01 | 2014-05-30 | Resverlogix Corp. | Spojine za preprečevanje in zdravljenje kardiovaskularnih bolezni |
| EP2005941A3 (de) | 2007-06-01 | 2009-04-01 | Henkel AG & Co. KGaA | Zellverjüngende Zusammensetzungen |
| WO2008152471A1 (en) | 2007-06-12 | 2008-12-18 | Coley Pharmaceutical Group, Inc. | Quinazoline derivative useful as toll-like receptor antagonist |
| KR20100035635A (ko) | 2007-06-21 | 2010-04-05 | 아이알엠 엘엘씨 | 단백질 키나제 억제제 및 그의 사용 방법 |
| AU2009262252B2 (en) | 2008-06-26 | 2013-05-02 | Resverlogix Corp. | Methods of preparing quinazolinone derivatives |
| CA2732087A1 (en) | 2008-08-05 | 2010-02-11 | Boehringer Ingelheim International Gmbh | Substituted naphthyridines and their use as medicaments |
| US20100093636A1 (en) * | 2008-10-06 | 2010-04-15 | Carolus Therapeutics, Inc. | Methods of treating inflammation |
| EP2362876B1 (en) | 2008-10-30 | 2013-12-11 | Circomed LLC | Thienotriazolodiazepine derivatives active on apo a |
| NZ594332A (en) | 2009-01-08 | 2013-09-27 | Resverlogix Corp | Compounds for the prevention and treatment of cardiovascular disease |
| JP2012519661A (ja) | 2009-03-06 | 2012-08-30 | エフ．ホフマン−ラ ロシュ アーゲー | 抗ウイルス性複素環化合物 |
| CN105859639A (zh) | 2009-03-18 | 2016-08-17 | 雷斯韦洛吉克斯公司 | 新的抗炎剂 |
| NZ807894A (en) | 2009-04-29 | 2025-08-29 | Amarin Pharmaceuticals Ie Ltd | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same |
| GB201007286D0 (en) | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
| DE102010048800A1 (de) | 2010-10-20 | 2012-05-10 | Merck Patent Gmbh | Chinoxalinderivate |
| CA2827585A1 (en) | 2011-02-16 | 2012-08-23 | Pivotal Therapeutics, Inc. | Statin and omega 3 fatty acids (epa, dha and dpa) for use in cardiovascular diseases |
| AU2012330885B2 (en) | 2011-11-01 | 2016-10-06 | Resverlogix Corp. | Oral immediate release formulations for substituted quinazolinones |
| DK2906531T3 (en) | 2012-10-15 | 2018-02-05 | Resverlogix Corp | APPLICABLE COMPOUNDS IN THE SYNTHESIS OF BENZAMIDE COMPOUNDS |
| CN104918912B (zh) | 2012-10-15 | 2017-02-22 | 阿尔比马尔公司 | 2‑氨基‑4,6‑二甲氧基苯甲酰胺和其他苯甲酰胺化合物的合成方法 |
| EA201690283A1 (ru) | 2013-08-21 | 2016-07-29 | Ресверлоджикс Корп. | Композиции и терапевтические способы для ускоренного регресса бляшки |
| BR112016003584A8 (pt) | 2013-08-21 | 2018-01-30 | Resverlogix Corp | composições farmaceuticas e uso das mesmas para regressão de placa acelerada |
| JO3789B1 (ar) | 2015-03-13 | 2021-01-31 | Resverlogix Corp | التراكيب والوسائل العلاجية المعتمدة لمعالجة الامراض المتعلقة بالمتممة |
-
2010
- 2010-04-21 BR BRPI1014956A patent/BRPI1014956B8/pt not_active IP Right Cessation
- 2010-04-21 HR HRP20182200TT patent/HRP20182200T1/hr unknown
- 2010-04-21 MX MX2016015962A patent/MX374414B/es unknown
- 2010-04-21 CN CN201080027599.8A patent/CN102458405B/zh not_active Expired - Fee Related
- 2010-04-21 PT PT10714825T patent/PT2421533T/pt unknown
- 2010-04-21 TR TR2018/18390T patent/TR201818390T4/tr unknown
- 2010-04-21 SI SI201031807T patent/SI2421533T1/sl unknown
- 2010-04-21 EP EP18193312.8A patent/EP3431086B1/en not_active Not-in-force
- 2010-04-21 KR KR1020117027609A patent/KR101892987B1/ko not_active Expired - Fee Related
- 2010-04-21 KR KR1020187023996A patent/KR20180096823A/ko not_active Ceased
- 2010-04-21 US US13/265,060 patent/US9757368B2/en active Active
- 2010-04-21 MX MX2011011048A patent/MX352614B/es active IP Right Grant
- 2010-04-21 AU AU2010239266A patent/AU2010239266B2/en not_active Ceased
- 2010-04-21 CN CN201710396072.6A patent/CN107252429B/zh not_active Expired - Fee Related
- 2010-04-21 JP JP2012507341A patent/JP5813626B2/ja not_active Expired - Fee Related
- 2010-04-21 LT LTEP10714825.6T patent/LT2421533T/lt unknown
- 2010-04-21 WO PCT/US2010/031870 patent/WO2010123975A1/en not_active Ceased
- 2010-04-21 DK DK10714825.6T patent/DK2421533T3/en active
- 2010-04-21 PL PL10714825T patent/PL2421533T3/pl unknown
- 2010-04-21 NZ NZ596117A patent/NZ596117A/en not_active IP Right Cessation
- 2010-04-21 EP EP10714825.6A patent/EP2421533B1/en active Active
- 2010-04-21 ES ES18193312T patent/ES2821018T3/es active Active
- 2010-04-21 CA CA2759241A patent/CA2759241C/en active Active
- 2010-04-21 KR KR1020197022099A patent/KR20190091564A/ko not_active Ceased
- 2010-04-21 KR KR1020207027594A patent/KR102215167B1/ko not_active Expired - Fee Related
- 2010-04-21 ES ES10714825T patent/ES2706651T3/es active Active
-
2011
- 2011-10-23 IL IL215799A patent/IL215799A/en active IP Right Grant
-
2014
- 2014-07-27 IL IL233822A patent/IL233822A/en active IP Right Grant
-
2017
- 2017-08-03 US US15/668,542 patent/US20170326143A1/en not_active Abandoned
- 2017-08-04 US US15/669,219 patent/US20170333419A1/en not_active Abandoned
-
2019
- 2019-06-14 US US16/441,793 patent/US20200129512A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012524794A5 (enExample) | ||
| ES2821018T3 (es) | Nuevos agentes antiinflamatorios | |
| CN1659144B (zh) | 喹啉和异喹啉衍生物、其制备方法以及作为炎症抑制剂的应用 | |
| JP2018507899A5 (enExample) | ||
| JP2012520867A5 (enExample) | ||
| JP3927175B2 (ja) | Ｎ−置換ヒドロキシピリミジノンカルボキサミド系ｈｉｖインテグラーゼ阻害薬 | |
| FI3788040T3 (fi) | Pyridatsinoneja parp7-inhibiittoreina | |
| HRP20141094T1 (hr) | 1,2,5-oksadiazoli kao inhibitori indolamin 2,3-dioksigenaze | |
| JP2011504497A5 (enExample) | ||
| JP2014521595A5 (enExample) | ||
| JP2010517946A5 (enExample) | ||
| JP2012502927A5 (enExample) | ||
| HRP20110670T1 (hr) | Derivati 4-(2-amino-1-hidroksietil)fenola kao agonisti beta-2 adrenergičkog receptora | |
| RU2010117156A (ru) | Гетероциклические соединения в качестве антагонистов crth2 рецептора | |
| JP2018518522A5 (enExample) | ||
| EA015358B1 (ru) | Хинолины и их терапевтическое применение | |
| CN101679311A (zh) | 喹唑啉化合物 | |
| Jain et al. | An explicative review on the progress of quinazoline scaffold as bioactive agents in the past decade | |
| CN110372666A (zh) | 喹唑啉类化合物作为egfr三突变抑制剂及其应用 | |
| JPWO2023064133A5 (enExample) | ||
| TW201202224A (en) | Optical pure quinazoline compounds | |
| HK1162148A (en) | Novel anti-inflammatory agents | |
| HK1162148B (en) | Novel anti-inflammatory agents | |
| HK40003375A (en) | Novel anti-inflammatory agents |